利妥昔单抗结合化疗治疗弥漫大B细胞淋巴瘤的效果及对生活质量的影响

Effect of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma and its influence on quality of life

目的探讨利妥昔单抗结合化疗治疗弥漫大B细胞淋巴瘤(DLBCL)的效果及对生活质量的影响。方法选取2019年8月至2021年8月我科收治的78例DLBCL患者为研究对象,以随机数字表法将其分为对照组和观察组,各39例。对照组采用常规化疗,观察组在对照组基础上结合利妥昔单抗治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的甲胎蛋白(AFP)、癌抗原125(CA125)及血清铁蛋白(SF)水平均低于对照组(P<0.05)。治疗后,观察组的B淋巴细胞低于对照组(P<0.05)。治疗后,观察组的躯体功能、情绪功能评分高于对照组,差异具有统计学意义(P<0.05)。结论利妥昔单抗结合化疗治疗DLBCL有助于提高治疗效果,改善患者血清相关因子水平,提高生活质量,但可能减少B淋巴细胞。

Objective To investigate the effect of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma(DLBCL)and its influence on quality of life.Methods A total of 78 patients with DLBCL admitted in our department from August 2019 to August 2021 were selected as the research objects and divided into control group and observation group by random number table method,with 39 cases in each group.The control group was treated with conventional chemotherapy,and the observation group was treated with rituximab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of alpha-fetoprotein(AFP),cancer antigen 125(CA125)and serum ferritin(SF)in the observation group were lower than those in the control group(P<0.05).After treatment,the B lymphocytes in the observation group was lower than that in the control group(P<0.05).After treatment,the scores of physical function and emotional function in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion Rituximab combined with chemotherapy in the treatment of DLBCL is helpful to improve the therapeutic effect,improve the levels of serum related factors,and improve the quality of life,but may reduce the B lymphocytes.